BioSpace News Archive

Business

uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2022 and highlighted recent progress across its business.

May 2, 2022
·
14 min read
Business

Orchard Therapeutics Announces Agreement Enabling Access and Reimbursement for Libmeldy for All Eligible MLD Patients in Germany

Orchard Therapeutics today announced it has reached an agreement with Gesetzliche Krankenversicherung Spitzenverband (GKV-SV) which will result in reimbursed access to Libmeldy ® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients in Germany who fall within the scope of the European marketing authorization.

May 2, 2022
·
8 min read
Drug Development

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that TP-03 (lotilaner ophthalmic solution, 0.25%) met the primary endpoint and all secondary endpoints in the Saturn-2 pivotal Phase 3 trial with a favorable safety profile, reinforcing its ability to resolve Demodex blepharitis, a highly prevalent eyelid disease.

May 2, 2022
·
8 min read
Business

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting.

May 2, 2022
·
6 min read
Business

Compugen to Release First Quarter 2022 on Monday, May 16, 2022

Compugen Ltd. announced today that the Company will release its first quarter 2022 financial results on Monday, May 16, 2022 before the U.S. financial markets open.

May 2, 2022
·
3 min read
Business

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

Syndax Pharmaceuticals, Inc. today announced that it will release its first quarter 2022 financial results on Monday, May 9, after the close of the U.S. financial markets.

May 2, 2022
·
1 min read
Business

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

Galmed Pharmaceuticals Ltd. provides today updated information on the Company’s scientific and clinical development programs and reports financial results for the three and twelve months ended December 31, 2021.

May 2, 2022
·
10 min read
Pharm Country

Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics, Inc. today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine.

May 2, 2022
·
7 min read
Business

CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

CytoSorbents Corporation announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group.

May 2, 2022
·
7 min read
Business

Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Axsome Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022.

May 2, 2022
·
12 min read